EZH2 and cancer: However, it should be noted that some in vitro or preclinical studies have shown the novel potential of new small molecules, e.g., the study by Zingg et al. (63), showed that EZH2 levels are upregulated in cancer cells after anti-CTLA-4 or IL-2 immunotherapies, leading to loss of tumor control.